Cell Division Protein FtsZ (ftsz) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary Cell Division Protein FtsZ (ftsz) pipeline Target constitutes close to 7 molecules. Out of which approximately 2 molecules are developed by companies and remaining by the universities/institutes. The latest report GMDHC22072TDB - Cell Division Protein FtsZ - Drugs In Development, 2022, outlays comprehensive information on the Cell Division Protein FtsZ (ftsz) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Cell Division Protein FtsZ (ftsz) - FtsZ is a protein encoded by the ftsZ gene. It is essential cell division protein that forms a contractile ring structure at the future cell division site. The regulation of the ring assembly controls the timing and the location of cell division. It recruits other cell division proteins to the septum to produce a new cell wall between the dividing cells. It binds GTP and shows GTPase activity. The molecules developed by companies in Phase I and Preclinical stages are 1 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 3 molecules, respectively. Report covers products from therapy areas Infectious Disease which include indications Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, Staphylococcus aureus Infections, Tuberculosis, Acinetobacter Infections, Bacillus Infections, Bacterial Pneumonia, Enterococcus faecium Infections, Skin And Skin Structure Infections (SSSI) Caused By Bacteria, Streptococcal Pneumonia, Vancomycin-Resistant Enterococcus faecium Infections and Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections.
Furthermore, this report also reviews key players involved in Cell Division Protein FtsZ (ftsz) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope - The report provides a snapshot of the global therapeutic landscape for Cell Division Protein FtsZ (ftsz) - The report reviews Cell Division Protein FtsZ (ftsz) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Cell Division Protein FtsZ (ftsz) targeted therapeutics and enlists all their major and minor projects - The report assesses Cell Division Protein FtsZ (ftsz) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Cell Division Protein FtsZ (ftsz) targeted therapeutics
Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Cell Division Protein FtsZ (ftsz) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Cell Division Protein FtsZ (ftsz) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Our reports have been used by over 10K customers, including:
Oral Mucositis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary This latest Pharmaceutical and Healthcare disease pipeline guide Oral Mucositis - Drugs In Development, 2022, provides an overview of the Oral Mucositis (Gastrointestinal) pipeline...
Non-Alcoholic Steatohepatitis (NASH) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary This latest Pharmaceutical and Healthcare disease pipeline guide Non-Alcoholic Steatohepatitis (NASH) - Drugs in Development by Stages, Target, MoA, RoA, Molecule...
Toll Like Receptor 3 (CD283 or TLR3) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Toll Like Receptor 3 (CD283 or TLR3) - Toll-like receptor 3 (TLR3) is a protein encoded by the TLR3 gene. It controls host immune response against...
120 pages •
By Infiniti Research Limited
• Apr 2022
Global Cytomegalovirus (CMV) Therapeutics Market 2022-2026 The analyst has been monitoring the cytomegalovirus (CMV) therapeutics market and it is poised to grow by $ 332.21 mn during 2022-2026, accelerating at a CAGR of 5.44% during the forecast period. Our report on the cytomegalovirus (CMV) therapeutics market provides...
120 pages •
By Infiniti Research Limited
• Apr 2022
Global Plasma Therapeutics Market 2022-2026 The analyst has been monitoring the plasma therapeutics market and it is poised to grow by $ 8.98 bn during 2022-2026 progressing at a CAGR of 6.1% during the forecast period. Our report on the plasma therapeutics market provides a holistic analysis, market size and forecast,...
Ischemia Reperfusion Injury Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary This latest Pharmaceutical and Healthcare disease pipeline guide Ischemia Reperfusion Injury - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key...
Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary According to the recently published report ’Bromodomain Containing Protein 3 - Drugs In Development, 2022’; Bromodomain...
350 pages •
By Roots Analysis Private Ltd.
• Mar 2022
INTRODUCTION Post the approval of the first aptamer-based therapy, Macugen®, by the US Food and Drug Administration (USFDA) in December 2004, there has been a significant increase in the R&D initiatives focused on evaluating the potential of aptamers as theranostic agents. In the following year, the outstanding annual sales...
Genital Herpes Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary This latest Pharmaceutical and Healthcare disease pipeline guide Genital Herpes - Drugs In Development, 2022, provides an overview of the Genital Herpes (Infectious Disease) pipeline...
Fibrosarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary This latest Pharmaceutical and Healthcare disease pipeline guide Fibrosarcoma - Drugs In Development, 2022, provides an overview of the Fibrosarcoma (Oncology) pipeline landscape. Fibrosarcoma...
Cancer
Therapy
Drug Development
World
By continuing to use this site you consent to the use of cookies on your device as described in our Cookie Policy unless you have disabled them.
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.